Four pharmaceutical companies have agreed to move to the next stage of the $26 billion settlement agreement on opioid claims after receiving approval from 42 out of 49 states, Washington, DC and five US territories. Under this agreement, money would be directed to rehabilitation programs in each participating state. The next step is for the states to determine whether their local governments want to participate in the settlement.